Rabbit NR1H4 Polyclonal Antibody | anti-NR1H4 antibody

NR1H4 Antibody

Cat. Num. AAA9611263

• Gene Names: NR1H4; BAR; FXR; HRR1; HRR-1; PFIC5; RIP14
• Reactivity: Human, Rat; Predicted: Pig, Bovine, Horse, Sheep, Rabbit, Dog
• Applications: Western Blot
• Purity: The antiserum was purified by peptide affinity chromatography using SulfoLink Coupling Resin (Thermo Fisher Scientific).
• Synonyms: NR1H4; Polyclonal Antibody; NR1H4 Antibody; BAR; Bile acid receptor; Farnesoid X activated receptor; Farnesoid X receptor; Farnesoid X-activated receptor; Farnesol receptor HRR 1; Farnesol receptor HRR-1; Farnesol receptor HRR1; FXR; HRR 1; HRR1; NR1H4_HUMAN; Nuclear receptor subfamily 1 group H member 4; Retinoid X receptor interacting protein 14; Retinoid X receptor-interacting protein 14; RIP 14; RIP14; RXR interacting protein 14; RXR-interacting protein 14; anti-NR1H4 antibody

• Host: Rabbit
• Reactivity: Human, Rat; Predicted: Pig, Bovine, Horse, Sheep, Rabbit, Dog
• Clonality: Polyclonal
• Isotype: IgG
• Specificity: NR1H4 Antibody detects endogenous levels of NR1H4.
• Purity/Purification: The antiserum was purified by peptide affinity chromatography using SulfoLink Coupling Resin (Thermo Fisher Scientific).
• Form/Format: Liquid; Phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
• Concentration: 1mg/ml (varies by lot)
• Sequence Length: 476

• Applicable Applications for anti-NR1H4 antibody: Western Blot (WB)
• Application Notes: WB: 1:500-1:2000
• Immunogen: A synthesized peptide derived from human NR1H4.
• Tissue Specificity: Liver and hepatocyte-related cells express mainly FXRalpha1-type isoforms with isoform 3 and isoform 4 in approximately equal proportions. In intestine and kidney mainly FXRalpha2-type isoforms are expressed with isoform 1 and isoform 2 in approximately equal proportions. Expressed in pancreatic beta cells and macrophages.
• Fragment: Fab Fragment
• Conjugate: Unconjugated
• Subcellular Location: Nucleus; Nucleus; Nucleus; Nucleus; Nucleus
• Preparation and Storage: Store at -20 degree C. Stable for 12 months from date of receipt.

Western Blot (WB)

(Western blot analysis of extracts from HeLa cells, using NR1H4 Antibody. The lane on the left was treated with blocking peptide.)

Western Blot (WB)

(Western blot analysis of extracts from various samples, using NR1H4 Antibody. Lane 1: 293, treated with blocking peptide; Lane 2: 293; Lane 3: Hela cells.)

Related Product Information for anti-NR1H4 antibody

Description: Ligand-activated transcription factor. Receptor for bile acids (BAs) such as chenodeoxycholic acid (CDCA), lithocholic acid, deoxycholic acid (DCA) and allocholic acid (ACA). Plays a essential role in BA homeostasis through the regulation of genes involved in BA synthesis, conjugation and enterohepatic circulation. Also regulates lipid and glucose homeostasis and is involved innate immune response (PubMed:10334992, PubMed:10334993, PubMed:21383957, PubMed:22820415). The FXR-RXR heterodimer binds predominantly to farnesoid X receptor response elements (FXREs) containing two inverted repeats of the consensus sequence 5'-AGGTCA-3' in which the monomers are spaced by 1 nucleotide (IR-1) but also to tandem repeat DR1 sites with lower affinity, and can be activated by either FXR or RXR-specific ligands. It is proposed that monomeric nuclear receptors such as NR5A2/LRH-1 bound to coregulatory nuclear responsive element (NRE) halfsites located in close proximity to FXREs modulate transcriptional activity (By similarity). In the liver activates transcription of the corepressor NR0B2 thereby indirectly inhibiting CYP7A1 and CYP8B1 (involved in BA synthesis) implicating at least in part histone demethylase KDM1A resulting in epigenomic repression, and SLC10A1/NTCP (involved in hepatic uptake of conjugated BAs). Activates transcription of the repressor MAFG (involved in regulation of BA synthesis) (By similarity). Activates transcription of SLC27A5/BACS and BAAT (involved in BA conjugation), ABCB11/BSEP (involved in bile salt export) by directly recruiting histone methyltransferase CARM1, and ABCC2/MRP2 (involved in secretion of conjugated BAs) and ABCB4 (involved in secretion of phosphatidylcholine in the small intestine) (PubMed:12754200, PubMed:15471871, PubMed:17895379). Activates transcription of SLC27A5/BACS and BAAT (involved in BA conjugation), ABCB11/BSEP (involved in bile salt export) by directly recruiting histone methyltransferase CARM1, and ABCC2/MRP2 (involved in secretion of conjugated BAs) and ABCB4 (involved in secretion of phosphatidylcholine in the small intestine) (PubMed:10514450, PubMed:15239098, PubMed:16269519). In the intestine activates FGF19 expression and secretion leading to hepatic CYP7A1 repression (PubMed:12815072, PubMed:19085950). The function also involves the coordinated induction of hepatic KLB/beta-klotho expression (By similarity). Regulates transcription of liver UGT2B4 and SULT2A1 involved in BA detoxification; binding to the UGT2B4 promoter seems to imply a monomeric transactivation independent of RXRA (PubMed:12806625, PubMed:16946559). Modulates lipid homeostasis by activating liver NR0B2/SHP-mediated repression of SREBF1 (involved in de novo lipogenesis), expression of PLTP (involved in HDL formation), SCARB1 (involved in HDL hepatic uptake), APOE, APOC1, APOC4, PPARA (involved in beta-oxidation of fatty acids), VLDLR and SDC1 (involved in the hepatic uptake of LDL and IDL remnants), and inhibiting expression of MTTP (involved in VLDL assembly (PubMed:12660231, PubMed:12554753, PubMed:15337761). Increases expression of APOC2 (promoting lipoprotein lipase activity implicated in triglyceride clearance) (PubMed:11579204). Transrepresses APOA1 involving a monomeric competition with NR2A1 for binding to a DR1 element (PubMed:11927623, PubMed:21804189). Also reduces triglyceride clearance by inhibiting expression of ANGPTL3 and APOC3 (both involved in inhibition of lipoprotein lipase) (PubMed:12891557). Involved in glucose homeostasis by modulating hepatic gluconeogenesis through activation of NR0B2/SHP-mediated repression of respective genes. Modulates glycogen synthesis (inducing phosphorylation of glycogen synthase kinase-3) (By similarity). Modulates glucose-stimulated insulin secretion and is involved in insulin resistance (PubMed:20447400). Involved in intestinal innate immunity. Plays a role in protecting the distal small intestine against bacterial overgrowth and preservation of the epithelial barrier (By similarity). Down-regulates inflammatory cytokine expression in several types of immune cells including macrophages and mononuclear cells (PubMed:21242261). Mediates trans-repression of TLR4-induced cytokine expression; the function seems to require its sumoylation and prevents N-CoR nuclear receptor corepressor clearance from target genes such as IL1B and NOS2 (PubMed:19864602). Involved in the TLR9-mediated protective mechanism in intestinal inflammation. Plays an anti-inflammatory role in liver inflammation; proposed to inhibit proinflammatory (but not antiapoptotic) NF-kappa-B signaling) (By similarity).

Post Translational Modifications: Acetylated by EP300. Lys-227 as is the major acetylation site for EP300; the dynamicly regulated acetylation inhibits heterodimerization with RXRA and transactivation activity. Deacetylated by SIRT1. Methylation may increase transactivation of target genes. Phosphorylation by PKC/PRKCA increases transactivation activity by promoting association with PPARGC1A. Sumoylated upon ligand binding.

Subunit Structure: Binds DNA predominantly as a heterodimer with RXRA. After activation by agonist binding interacts with coactivators. Interacts with NCOA1, NCOA2, PPARGC1A, CARM1, SETD7, PRMT1, GPS2, SMARCA4 and MED1 (PubMed:15202934, PubMed:14684751, PubMed:15187081, PubMed:15471871, PubMed:15911693, PubMed:17895379, PubMed:18755856, PubMed:19805516, PubMed:23462506, PubMed:12718892, PubMed:12718893, PubMed:18621523, PubMed:18391212, PubMed:19410460, PubMed:19586769). Interacts with EP300 and SMARCD1 (By similarity). Interacts with XRCC5 and XRCC6; decreasing NR1H4/FXR transactivation activity towards ABCB11/BSEP (PubMed:19833092). Interacts with PAGR1 AND NCOA6; indicative for an association with an MLL2/MLL3 complex (ASCOM) (PubMed:19556342).

Similarity: Belongs to the nuclear hormone receptor family. NR1 subfamily.

NCBI and Uniprot Product Information

• NCBI GI #: 332801015
• NCBI GeneID: 9971
• NCBI Accession #: NP_001193906
• NCBI GenBank Nucleotide #: NP_001193906.1
• UniProt Accession #: Q96RI1
• Molecular Weight: Observed: 48 kDa; Predicted: 56 kDa
• NCBI Official Full Name: bile acid receptor isoform 1
• NCBI Official Synonym Full Names: nuclear receptor subfamily 1 group H member 4
• NCBI Official Symbol: NR1H4
• NCBI Official Synonym Symbols: BAR; FXR; HRR1; HRR-1; PFIC5; RIP14
• NCBI Protein Information: bile acid receptor
• UniProt Protein Name: Bile acid receptor
• Protein Family: Bile acid receptor
• UniProt Gene Name: NR1H4
• UniProt Synonym Gene Names: BAR; FXR; HRR1; RIP14; RXR-interacting protein 14
• UniProt Entry Name: NR1H4_HUMAN

NCBI Description

This gene encodes a ligand-activated transcription factor that shares structural features in common with nuclear hormone receptor family members. This protein functions as a receptor for bile acids, and when bound to bile acids, binds to DNA and regulates the expression of genes involved in bile acid synthesis and transport. Alternatively spliced transcript variants encoding different isoforms have been described. [provided by RefSeq, Feb 2016]